Improving our understanding and diagnosis of life-threatening genetic disorders of the innate and adaptive immune system in the primary immune deficiency (PID) project.

Overcoming the main current diagnostic challenges in hepatology practice in the liver project.

Improving treatment outcome prediction by characterizing the tumor and tumor micro-environment at single-cell level during treatment with immune-checkpoint blockers in the Pointillism project.

Inducing drug-free remission in spondyloarthritis patients by early treatment with biologicals under guidance of single-cell and epigenetic profiling in the Spartacus project.

Developing a platform to find nanobody constructs that can cross the blood-brain barrier, as a way of treating brain diseases in the blood-brain-barrier (BBB) project.

Targeting the microbial community in our gut as a way of treating inflammatory bowel disease (IBD) in the Mimosa project.

Catching nitrogen-fixing bacteria (Rhizobia) to introduce high protein-containing soybean for a sustainable agriculture in Flanders in the Soy project.

Developing pan-influenza neutralizing biologics to treat and prevent viral pneumonia in the Ibcori project.

An in-dept characterization of the dynamic immune response to coronavirus SARS-CoV-2 in the Contagious project.

Investigating immune stimulators as a treatment option for patients with acute hypoxic respiratory failure due to COVID-19 in the Sarpac project.

Investigating anti-rheumatic drugs as a treatment option for patients with a cytokine storm due to COVID-19 in the Covaid project.

Pointillism 2.0 has the goal to determine whether a cancer patient will benefit from immunotherapy treatment.

The BE.Amycon aims to establish a Belgian center of expertise for people with peripheral amyloidosis by joining forces of VIB researchers, a state-of-the-art diagnostic platform, and clinicians from various disciplines and different institutes.

The Biopet project aims at using biotechnology to produce sustainable pet food.